Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study
Digestive and Liver Disease · 2025-11 · 57 (11) · 2109-2113
DOI: 10.1016/j.dld.2025.07.037 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025-11. Verfasst von Fabio Salvatore Macaluso und 21 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory bowel disease Unit, A.O.O.R. "Villa Sofia-Cervello", Hospital, Viale Strasburgo 233, Palermo 90146, Italy. Electronic address: fsmacalus…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Piperidines, Pyrimidines, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Janus kinase inhibitors (JAKi), including tofacitinib (TOFA, pan-JAK) and filgotinib (FILGO, selective JAK1), are oral agents approved for moderate-to-severe ulcerative colitis (UC). Head-to-head comparative data in real-world settings are limited. AIM: To compare effectiveness and safety of TOFA and FILGO in patients with UC. METHODS: We conducted a multicenter cohort study using data from the Sicilian Network for Inflammatory Bowel Diseases. Consecutive adult UC patients treated with TOFA or FILGO and ≥16 weeks of follow-up were included. Propensity score weighting (IPTW) was used to balance baseline characteristics. RESULTS: 263 patients were included (TOFA: n = 171; FILGO: n = 92). At week 24, steroid-free clinical remission was observed in 58.8 % with TOFA and 44.9 % with FILGO (IPTW-adjusted OR: 1.37; 95 % CI: 0.76-2.49; P = 0.30). Clinical response rates at 24 weeks were 63.6 % for TOFA and 59.0 % for FILGO (IPTW-adjusted OR: 1.13; 95 % CI: 0.62-2.08; P = 0.69). Treatment persistence at 24 weeks was 83.5 % for TOFA vs. 76.4 % for FILGO (HR: 0.78; P = 0.30). Adverse event rates were higher with TOFA (12.7 vs. 5.4 per 100 person-years), though not statistically significant (P = 0.152). CONCLUSION: TOFA and FILGO demonstrated similarly high effectiveness and persistence in real-world UC patients. Both had acceptable safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory bowel disease Unit, A.O.O.R. "Villa Sofia-Cervello", Hospital, Viale Strasburgo 233, Palermo 90146, Italy. Electronic address: fsmacaluso@gmail.com.
- Inflammatory bowel disease Unit, A.O.U. Policlinico "G. Martino", Messina, Italy.
- Gastroenterology Unit, A.O. "Guzzardi", Vittoria, Italy.
- Gastroenterology and Hepatology Unit, PROMISE, A.O.U. Policlinico "P. Giaccone", Palermo, Italy.
- Gastroenterology and Endoscopy Unit, A.R.N.A.S. "Civico Di Cristina Benfratelli", Palermo, Italy.
- Inflammatory Bowel Disease Unit, A.O. "Cannizzaro", Catania, Italy.
Zitieren
APA
Macaluso, F. S., Fries, W., Viola, A., De Francesco, C., Belluardo, N., Giangreco, E., Cappello, M., Ajovalasit, R., Mocciaro, F., Scrivo, B., Privitera, A. C., Distefano, M. E., Vitello, A., Ferracane, C., Muscarella, S., Li Voti, R., Mistretta, G., Renna, S., Casà, A., …, & Sicilian Network for Inflammatory Bowel Disease (SN-IBD) (2025). Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study. Digestive and Liver Disease, 57(11), 2109-2113. https://doi.org/10.1016/j.dld.2025.07.037
Vancouver
Macaluso FS, Fries W, Viola A, De Francesco C, Belluardo N, Giangreco E, et al. Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study. Digestive and Liver Disease. 2025;57(11):2109-2113. doi:10.1016/j.dld.2025.07.037
BibTeX
@article{Macaluso2025,
author = {Macaluso, Fabio Salvatore and Fries, Walter and Viola, Anna and De Francesco, Clara and Belluardo, Nunzio and Giangreco, Emiliano and Cappello, Maria and Ajovalasit, Roberto and Mocciaro, Filippo and Scrivo, Barbara and Privitera, Antonino Carlo and Distefano, Maria Emanuela and Vitello, Alessandro and Ferracane, Concetta and Muscarella, Stefano and Li Voti, Raffaele and Mistretta, Giuseppe and Renna, Sara and Casà, Angelo and Ventimiglia, Marco and Orlando, Ambrogio and Sicilian Network for Inflammatory Bowel Disease (SN-IBD), Sicilian Network for Inflammatory Bowel Disease (SN-IBD)},
title = {Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study},
journal = {Digestive and Liver Disease},
year = {2025},
volume = {57},
number = {11},
pages = {2109--2113},
doi = {10.1016/j.dld.2025.07.037}
}
EUVIMED